EIS Investment Opportunity
Round 3 — £500,000 at 7.50p per share. A time-sensitive, de-risked entry point.
EIS Opportunity: Round 3
Building on significant progress from our SEIS, EIS Round 1 and EIS Round 2 funding, we now offer Round 3 investors a unique, time-sensitive entry point.
- A one-time opportunity at a de-risked entry price
- Available for the next £500,000 of investment only
- Highly de-risked — SEIS, EIS Round 1 & Round 2 already closed
- EIS Advance Assurance secured · Ordinary equity structure
- Our current valuation is 12.65p per share
- Capped at £2,000,000 in the larger Round 4
- Post-growth valuation, higher entry price
- Available after Round 3 is fully subscribed
Use of Funds
The Round 3 EIS funds of £1,500,000 will be deployed as follows to accelerate R&D, manufacturing and commercialisation.
R&D & Lab Equipment
£300,000Assays, crop trials, clinical mapping
BioCube Components
£480,000Fabrication, sensors, installation
IP & Certification
£120,000Patents, GACP, ISO 22000
Commercial Team
£300,000Sales, marketing, business development
Operations & Working Capital
£240,000Day-to-day operations
Contingency
£60,000Reserve fund
Building Momentum
Investor Validation
Secured SEIS, EIS Round 1 and EIS Round 2 funding from 130 investors, demonstrating strong investor confidence and market validation.
Non-Dilutive Funding
Successfully secured £35,000 in grants for R&D and facility upgrades.
Streamlined Processes
Clean, transparent round mechanics with sensible terms ensuring a straightforward investment process.
Strengthened Leadership
Expanded team, advisory board and partner network, bringing expertise and strategic guidance.
Enhanced Governance
Upgraded financial controls, monthly reporting cadences, and lab QA processes.
Valuation Growth
Achieved valuation increase from £3.75m to £12.65m — compelling for early EIS Round 3 investors.
Ready to Invest?
Contact us to register your interest in EIS Round 3 before the allocation fills.
